Lead Sponsor

Gilead Sciences

Collaborators

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

•HIV-1 positive patients who have maintained an HIV-1 viral load \<200 copies/mL, for at least 3 months.
•Patients must be on their first HAART or have documented viral suppression on a PI-based regimen at the time of any prior change in therapy.
•HAART must consist of either:
•1. A PI (with or without ritonavir) + at least 2 NRTIs or
•2. An NNRTI + at least 2 NRTIs.
•Negative serum pregnancy test.

•Patients who have taken any NNRTI prior to their current therapy.
•Patients who have taken a NRTI-only therapy for greater than 7 days prior to their current therapy.
•Patients who are currently taking EFV+FTC+TDF.
•Patients who have a creatinine clearance of \<60 mL/min by Cockcroft-Gault estimation.
•Patients who have experienced virologic failure with any previous ARV therapy.
•Patients who have documented resistance to any of the study agents at any time in the past.